= Members Only
Toxicology for Industrial and Regulatory Scientists
Amy M. Avila, PhD
Dr. Avila earned her Bachelor of Science degree in Biochemistry from the University of Delaware. She then received her PhD in pharmacology from Georgetown University, with a focus in neuropharmacology. Her thesis research involved the study of neuronal nicotinic acetylcholine receptors and their functional regulation by nicotine and nerve growth factor. After receiving her PhD, she conducted postdoctoral research at the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. She worked in the Neurogenetics Branch studying the neuromuscular disease Spinal Muscular Atrophy and investigating possible pharmacological therapies using cell-based models and transgenic mouse models. In 2006, Dr. Avila joined the Food and Drug Administration where she is currently serving as a pharmacologist/toxicologist reviewer in the Division of Psychiatry Products in the Center for Drug Development and Research (CDER). She is an active member of the Committee for Advanced Scientific Education in CDER, was a member of the Education Subcommittee of the Pharmacology/Toxicology Coordinating Committee and has contributed to the development of a training course for new pharmacologist/toxicologist reviewers. Her areas of interest are psychopharmacology, and assessment of seizures in nonclinical drug development.
Russell Bialecki, PhD
Dr. Bialecki is currently Lead Safety Pharmacologist for Infection, Neuroscience and in-licensing opportunities within the Department of Drug Safety and Metabolism at AstraZeneca Pharmaceuticals in Waltham, MA. He manages preclinical safety programs in support of AstraZeneca Pharmaceuticals discovery and clinical development programs. Dr. Bialecki has engaged in pharmaceutical R&D related to integrative physiology/pharmacology for 24 years with expertise in CNS, respiratory and cardiovascular functional assessments in vivo and in vitro.
Dr. Bialecki received his PhD degree in Medical Physiology from the Medical College of Pennsylvania in 1988 with a subsequent Postdoctoral Research Fellowship at Brigham and Women's Hospital and Research Fellowship in Medicine at Harvard Medical School. During this time he cultivated professional interests in cardiovascular/CNS physiology and pharmacology. Since 1991 he has held positions of increasing responsibility in R&D working with AstraZeneca and its predecessors as Principal Bioscientist, Project Manager and Director, Safety Pharmacology. He has significantly contributed to the nomination of more than 40 candidate compounds into clinical and commercial development and is co-inventor on several pharmaceutical patents. Dr. Bialecki is the author of numerous peer-reviewed research papers and book chapters on various cardiovascular, respiratory and neuroscience topics. He regularly reviews research manuscripts for several physiology and pharmacology journals and is editor for the Journal of Pharmacology and Toxicological Methods. Dr. Bialecki participates in several scientific societies including the American Heart Association, Society for Neuroscience, Society for Toxicology, American Pain Society and the Biophysical Society. He is an active participant in the Safety Pharmacology Society having served as a member of the Board of Directors and the Academic Outreach Committee.
Matthew S. Bogdanffy, PhD, DABT, ATS
Dr. Bogdanffy received his PhD in toxicology from Northeastern University, Boston, Massachusetts and was a postdoctoral fellow at the CIIT Centers for Health Research in North Carolina. He spent 17 years with the DuPont Company in various roles including Research Manager and Director of Biochemical and Molecular Toxicology. He has been with Boehringer Ingelheim Pharmaceuticals in Ridgefield Connecticut since 2004 and is Director of Regulatory Toxicology. Dr. Bogdanffy has served on the editorial board of several toxicology journals including Associate Editor for Toxicological Sciences. He has authored more than 85 research articles, reviews and book chapters. He is a past member of Council for the Society of Toxicology, is an Adjunct Professor at the University of Connecticut, a Diplomate of the American Board of Toxicology and a member of the Board of Directors and Fellow of the Academy of Toxicological Sciences.
William J. Brock, PhD, DABT, Fellow ATS
Dr. Brock, Otsuka Pharmaceuticals and Brock Scientific Consulting, provides pharmacology and toxicology advice for early- through late-stage pharmaceutical development for worldwide regulatory submissions. He also provides scientific and regulatory consulting advice and safety and risk assessments to clients in the chemical, medical device, food and consumer product industries. His primary research interests include human health risk and exposure assessments with an interest in the mechanisms of toxicity associated with human exposures to xenobiotics. In addition, Dr. Brock maintains an expertise in the inhalation toxicology of halogenated hydrocarbons and ocular and dermal toxicology of xenobiotics. Dr. Brock has authored or co-authored more than 50 publications, and has authored or co-authored several book chapters and is a co-editor on two toxicology and regulatory toxicology books. He has served as a member and in a leadership capacity for several national and international toxicology organizations (IPEC, ACC, ECETOC, PAFT, HESI, ASHRAE, etc.) and has been an invited speaker for the Committee on Toxicology, National Research Council, International Pharmaceutical Excipients Council (IPEC), American Association of Pharmaceutical Scientists (AAPS), the Chinese government and others. Dr. Brock is currently an expert reviewer for IPEC’s Excipients Panel. Dr. Brock is a Diplomate of the American Board of Toxicology (ABT) and a Fellow of the Academy of Toxicological Sciences (ATS), and has served as Board member and President for both ABT and ATS. Dr. Brock has served in various leadership capacities or as a member of various professional organizations and committees for the American College of Toxicology, Society of Toxicology, Roundtable of Toxicology Consultants and the Drug Information Association. Dr. Brock is an Associate Editor for the International Journal of Toxicology.
Lorrene A. Buckley, PhD, DABT, ATS
Dr. Buckley is a board-certified toxicologist with over 30 years of experience in the active practice of toxicology. She earned her Masters degree in Toxicology at the University of Arizona and a doctorate, also in Toxicology, at the University of North Carolina in Chapel Hill in collaboration with the laboratories of the National Institute of Environmental Health Sciences and the US Environmental Protection Agency.
Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic and applied toxicology research and risk assessment in the industrial chemical, agrochemical, and pharmaceutical industries. In her current position as a Senior Research Fellow at Eli Lilly & Company, she is responsible for the design and execution of nonclinical safety assessment programs, including general and other toxicology studies, as well as for nonclinical aspects of global regulatory submissions and interactions for a variety of drugs in the development and commercialization phases. Dr. Buckley has authored the pharmacology/toxicology sections of numerous regulatory documents including pre-IND packages briefing documents, INDs/IMPDs, BLAs/NDAs, investigator brochures, annual reports, as well as the safety information on product labels/package inserts.
Dr. Buckley has also authored numerous journal articles and book chapters concerning the toxicologic assessment of environmental contaminants as well as approaches to pharmaceutical safety assessment. She has served as a Board member of the Board of the American Board of Toxicology (ABT) and on the Councils of the American College of Toxicology (ACT) and the Society of Toxicology (SOT). She is board-certified by the ABT and is a Fellow of the Academy of Toxicological Sciences (ATS).
Gary R. Burleson, PhD
Dr. Burleson received his PhD from the Medical College of Wisconsin with Postdoctoral training at the University of Notre Dame. His background includes clinical experience at Milwaukee County General Hospital, academic appointments at the University of Notre Dame and North Carolina State University, government regulatory experience at the USEPA, and pharmaceutical experience in drug discovery at Procter & Gamble. He is President and CEO of BRT-Burleson Research Technologies, Inc., a CRO specializing in Immunotoxicology since 1996, He is Senior Editor of Methods in Immunotoxicology, Volumes 1 and 2; a member of the editorial board of the Journal of Immunotoxicology and International Journal of Toxicology; Scientific Consultant, Science Review Board, US EPA; and is past president of the Immunotoxicology Discussion Group (IDG) and the SOT Immunotoxicology Specialty Section; served as Conference Chair, Immunotoxicology V Meeting; Organizer, Continuing Education Course entitled “Immunotoxicology,” for 19th Annual Society of Toxicologic Pathology Meeting. He serves several times a year for NIH-NIAID Grant and Contract Reviews.
Mary Beth Genter, PhD, DABT, Fellow, ATS
Dr. Mary Beth Genter has been an academic toxicologist since completing graduate studies in the Integrated Toxicology Program at Duke University and postdoctoral studies at the Chemical Industry Institute of Toxicology in 1990. Dr. Genter’s background is in neurotoxicology, and she has a special interest in the olfactory system, as a target for toxicant-induced damage, as a model for studying neuronal plasticity, and as a route of drug delivery. Prior to joining the University of Cincinnati Department of Environmental Health, Dr. Genter was employed by the North Carolina State University Department of Toxicology, where, among other responsibilities, she served as the toxicologist for the North Carolina Cooperative Extension Service. She also served as a member of the North Carolina Secretary’s Scientific Advisory Board on Toxic Air Pollutants. Dr. Genter has published over 70 peer-reviewed manuscripts, and served as an advisor for the US EPA during the reevaluation of the IRIS naphthalene document. Dr. Genter is a diplomate of the American Board of Toxicology (ABT; 1992–present) and served on the ABT Board of Directors (2004–008). She is currently the Editor-in-Chief of International Journal of Toxicology, and a reviewer for approximately two-dozen papers for other journals per year.
Dr. Genter currently serves as member of the Society of Toxicology’s Scientific Program Committee and as a member of the National Toxicology Program’s Board of Scientific Counselors. She is a member of the American College of Toxicology, the Society of Toxicology, the Association for Chemoreception Sciences, the Academy of Toxicological Sciences, and Sigma Xi.
Hanan Ghantous, PhD, DABT
Hanan Ghantous, PhD, DABT, is a Pharmacology/Toxicology supervisor at the Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration. Since joining the FDA in 2001, she has evaluated pharmacology/toxicology data to support the safe clinical development of small molecule drugs and biological products with anti-viral, oncology and internal medicine indications. Dr. Ghantous has presented at national and international scientific and regulatory meetings, has served on several FDA committees, has been involved in writing Guidance documents and has represented the Agency at various public forums. She is a member of the Society of Toxicology and served on the Continuing Education Committee of SOT (2010–2013), and was the president of the Biotechnology Specialty Section (2012–2013). She also served on council of the American College of Toxicology (2011–2013) and in 2013 was elected as is VP of the American College of Toxicology. Dr. Ghantous is the president of the Board of Directors of the American Board of Toxicology (2013–2014).
Before coming to FDA, Dr. Ghantous worked for approximately 10 years at the DuPont Company, starting her career as a Research Toxicologist at DuPont Haskell Laboratory, with responsibilities of a Study Director. Dr. Ghantous filled a number of other positions at the DuPont Company including Project Registration Manager, US Regulatory Toxicologist, and NAFTA Regulatory Toxicologist in the Crop Protection Division.
Dr. Ghantous has a BSc in Pharmacy from the University of Baghdad, Iraq, an MSc in Pharmacology from the University of Strathclyde, Scotland and a PhD in Toxicology from the University of Uppsala, Sweden. She is a Diplomat of the American Board of Toxicology (DABT) and did postdoctoral training at the Department of Anesthesiology, Pharmacology/Toxicology Division, University of Arizona. Dr. Ghantous has over 23 years of combined experience in general and regulatory toxicology, and has published numerous pier reviewed scientific papers.
Robert L. Hall, DVM, PhD
Following graduation from The Ohio State University (OSU) College of Veterinary Medicine in 1977 and two years in private practice, Dr. Hall returned to OSU for a clinical pathology residency. He became board certified in veterinary clinical pathology in 1982 and completed a PhD in veterinary pathology at Colorado State University in 1985. Dr. Hall joined Covance (Hazleton) in October 1985. He and three other board-certified veterinary clinical pathologists are responsible for scientific matters pertaining to clinical pathology and for reporting clinical pathology findings from toxicology, safety pharmacology, and metabolism studies. In his primary role, he has authored approximately 4000 clinical pathology reports for preclinical studies. He has also authored chapters for several books including Toxicologic Pathology: Nonclinical Safety Assessment, Principles and Methods of Toxicology, Comprehensive Toxicology, and Animal Models in Toxicology. A member of the American College of Veterinary Pathologists (ACVP), American Society of Veterinary Clinical Pathology (ASVCP), and Society of Toxicologic Pathology (STP), Dr. Hall has served on editorial boards and as chair of the ACVP Examination and Government Policy Committees, chair of the ASVCP Regulatory Affairs Committee, an ACVP Councilor, and the ACVP representative to the American Board of Veterinary Specialties of the AVMA. He would rather be fishing.
Ernie Harpur, BSc, PhD, ATS, FBTS
Following periods of doctoral and postdoctoral research in toxicology, Ernie spent 13 years engaged in teaching and research in academia where his research interests centered on investigations of mechanisms of toxicity and the relationship between pharmacokinetics and toxicity. Ernie subsequently gained 21 years of operational and managerial experience in nonclinical safety evaluation within pharmaceutical industry based in Europe and the USA. He transitioned from Head of General and Investigative Toxicology, through Senior Director of Toxicology and Scientific Director of a development site to Global Head of Scientific Affairs and Regulatory Standards within Drug Safety Assessment in Sanofi-Aventis. Since leaving industry in 2010, Ernie has held an honorary position in the Institute of Cellular Medicine at Newcastle University UK and engaged in various scientific advisory roles. He has served as Scientific Meetings Secretary of the British Toxicology Society and is currently a member of the BTS Executive Committee. Ernie has also contributed to EUROTOX as President and chair of several committees. He is a Fellow of the British Toxicology Society, a Fellow of the Academy of Toxicological Sciences and an honorary member of EUROTOX. He has served on several expert committees, including the Safety, Efficacy and Adverse Reactions Committee of the UK Committee on Safety of Medicines. He has had leadership roles in a number of scientific consortia on both sides of the Atlantic serving as Chair of the Washington DC-based ILSI Health and Environmental Sciences Institute Renal Biomarkers Committee (now Scientific Advisor to this committee) and Vice Chair of the ILSI HESI Emerging Issues Committee and as a member of the Advisory Committee of the Predictive Safety Testing Consortium of the Critical Path Institute. Currently, he is a member of the Board of Trustees, Executive Committee and Program Strategy and Stewardship Committee of ILSI HESI and chair of the Scientific Advisory Board of the UK public private partnership, Stem Cells for Safer Medicines. He has published more than 90 journal articles, reviews and book chapters and is a member of the editorial board of Toxicology Letters and Human & Experimental Toxicology.
Melanie T. Hartsough, PhD
Dr. Hartsough is a Senior Consultant at Biologics Consulting Group, Inc. She utilizes her expertise in the strategy and development of drug products to assist clients with nonclinical development of biologics and small molecules.
Dr. Hartsough received her PhD in Pharmacology from Pennsylvania State University, College of Medicine. After a postdoctoral fellowship at NIH, Melanie joined US FDA’s Center for Biologic Evaluation and Research (CBER), Division of Therapeutic Proteins, as a full-time product reviewer. During this time, she performed chemistry, manufacturing and controls (CMC) and immunogenicity reviews for biotechnology-derived products. In 2004, Melanie transferred to the Division of Biologic Oncology Products, Center for Drug Evaluation and Research (CDER), as a pharmacology/toxicology reviewer. During this time she also performed consult reviews for the Office of Vaccines Research and Review and Office of Blood Research and Review, CBER. In 2006, she left the US FDA and joined Aclairo Pharmaceutical Development Group, Inc as a consultant. In 2007, Melanie left Aclairo and joined the Biologics Consulting Group, Inc.
Dr. Hartsough’s expertise focuses primarily on US FDA regulatory issues and strategies associated with nonclinical pharmacology and toxicology development of biologic (including cell and gene therapies, prophylactic and therapeutic vaccines, blood products and recombinant therapeutic proteins and monoclonal antibodies) and small molecule products. She is able to aid sponsors in the overall strategy and development of drug products, including relevant species, pharmacokinetic, tissue cross-reactivity, comparability and immunogenicity issues. For immunogenicity-related issues, her expertise encompasses both nonclinical and clinical disciplines. Melanie is able to provide general regulatory advice, perform reviews of the nonclinical development plan to determine regulatory gaps, design and interpret toxicology studies, interface with toxicology CROs, aid in the preparation of regulatory submissions (prepreIND, preIND, IND, BLA, NDA, response to hold, etc) and participate in US FDA meetings with the sponsor.
Kenneth L. Hastings, DrPH, DABT, Fellow ATS Dr.
Hastings received his Doctor of Public Health degree from the School of Public Health, University of North Carolina at Chapel Hill, in 1987. He completed his doctoral research at the Chemical Industry Institute of Toxicology under the direction of Dr. Jack Dean. Dr. Hastings then served as a US Peace Corps Volunteer in Fiji under the Permanent Secretary for Health. From 1988–1991 Dr. Hastings completed a postdoctoral fellowship and was then appointed Research Associate in the Pharmacology/Toxicology Research Laboratory, Department of Anesthesiology, College of Medicine, University of Arizona, under the direction of Dr. A. Jay Gandolfi. From 1991–2007 Dr. Hastings worked in the Center for Drug Evaluation and Research, US Food and Drug Administration, in various positions: pharmacology/toxicology reviewer in the Division of Anti-viral Drug Products (1991–1997), pharmacology/toxicology supervisor in the Division of Special Pathogen and Immunologic Drug Products (1997–2003), and as an Associate Director in the Office of New Drugs (2003–2007). Dr. Hastings served on numerous committees and working groups while at FDA, including lead representative for CDER/FDA on the ICCVAM validation of the murine local lymph node assay and as lead negotiator on ICH S8 (Immunotoxicology Evaluation of New Drugs). From 2007–2014 Dr. Hastings was Associate Vice President for Regulatory Policy, Sanofi US, serving as corporate representative on numerous industry working groups dealing with regulatory science and policy. Dr. Hastings has served in many professional societies (President, Society of Toxicology Immunotoxicology Specialty Section; President, American College of Toxicology; President, SOT Regulatory and Safety Evaluation SS). Dr. Hastings served as President of the American Board of Toxicology and has numerous publications, included editor of books on use of mini-pigs in biomedical research and international standards for nonclinical safety evaluation of medical products. Dr. Hastings is currently an independent consultant specializing in toxicology studies in drug development.
A. Wallace Hayes, PhD, DABT, FATS, FIBiol, FACFE, ERT
Dr. Hayes is a toxicologist with over 35 years of experience in industry and academics. He holds degrees from Auburn University (PhD and MS) and Emory University (AB). Dr. Hayes was a NSF predoctoral fellow at Auburn University, a NIH individual postdoctoral fellow at the Vanderbilt University School of Medicine, a NATO Senior Scientist at the Central Veterinary Laboratory in Weybridge, England and held a NIH Research Career Development Award.
Dr. Hayes has held tenured Professorships at the University of Alabama, the University of Mississippi Medical Center and Wake Forest University School of Medicine. Dr. Hayes has served on committees and expert panels for the National Academy of Sciences, the National Institutes of Health, the Environmental Protection Agency and the Department of Defense. Dr. Hayes has served on a number of GRAS Expert Panels. He currently serves on the US FDA Food Safety Committee.
Dr. Hayes has authored more than 225 peer-reviewed publications, is the editor of Hayes’ Principles and Methods of Toxicology, 6th edition, Human and Experimental Toxicology, Cutaneous and Ocular Toxicology and co-editor of the Target Organ Toxicity Series. He is the Editor-in-Chief, Food and Chemical Toxicology. Dr. Hayes is a past Secretary-General of IUTOX (two terms), past treasurer and board member of the American Board of Toxicology, a past president of the American College of Toxicology, the Toxicology Education Foundation, and the Academy of Toxicological Sciences and a past member of the council of the Society of Toxicology. Dr. Hayes is a diplomate of the American Board of Toxicology, the Academy of Toxicological Sciences, the American Board of Forensic Medicine, and the American Board of Forensic Examiners. He is a Fellow of the Academy of Toxicological Sciences, the Institute of Biology (UK), the American College of Forensic Examiners and the American College of Nutrition. Dr. Hayes is a registered toxicologist in the European Union (ERT) and a certified nutrition specialist (food safety). Dr. Hayes was honored by the Society of Toxicology in 2006 with the Society's Merit Award, by the Mid-Atlantic Society of Toxicology with its Ambassador Award in 2012, by the American College of Toxicology in 2012 with its Distinguished Scientist Award and by the International Dose-Response Society in 2013 with its Outstanding Leadership Award. Dr. Hayes was named a Distinguished Fellow by the American College of Toxicology in 2013.
Kok Wah Hew, PhD, DABT
Dr. Hew is a Scientific Director at the Global Drug Safety Research and Evaluation Department of Takeda Pharmaceutical Company. His current responsibilities include providing scientific and strategic leadership for the nonclinical development of new drug candidates, writing the nonclinical summaries of regulatory documents, and managing toxicological issues associated with these candidates. He received his PhD in Anatomy and Cell Biology from the University of Michigan, Ann Arbor, Michigan, USA. Following graduation, he worked as a Study Director in Reproductive Toxicology at Ciba-Geigy Corporation and Novartis Pharmaceuticals Corporation. He also served as the Manager of Reproductive Toxicology at Springborn Laboratories; Senior Manager, and subsequently Associate Director in the Nonclinical Drug Safety Evaluation Department of Purdue Pharma; and Director of Toxicology at Emisphere Technologies, Inc. He has more than 20 years of experience in drug safety assessment, with special interests in reproductive toxicology and juvenile animal toxicity studies. In addition to authoring numerous toxicology reports and regulatory documents, he is also the lead or co-author of a number of peer reviewed journal articles and book chapters. Dr. Hew was a member of the Editorial Board in the Reproductive Toxicology journal, and is currently a member of the Editorial Board of the International Journal of Toxicology as well as the Journal of Toxicological Sciences. Since 2010, he is the Course Director and a speaker of the annual week-long course Toxicology for Industrial and Regulatory Scientists, sponsored by the American College of Toxicology (ACT). Dr. Hew is a Diplomate of the American Board of Toxicology. He is also a member of the US Society of Toxicology (SOT), ACT, US and Japanese Teratology Societies, Middle Atlantic Reproduction and Teratology Association (MARTA), and the Developmental and Reproductive Toxicology Technical Committee in Health and Environmental Sciences Institute of the International Life Sciences Institute. In the US SOT and Teratology Society, he has served on various committees, including the Chair of the Continuing Education Committee in both societies. He is also a past-president of MARTA.
Timothy J. McGovern, PhD
Dr. Tim McGovern is currently an Office Associate Director for Pharmacology/Toxicology in FDA CDER’s Office of New Drugs where he interacts with nonclinical review teams in the review of IND, NDA, and BLA submissions, advises Office Directors on nonclinical issues, and is involved in development of policy and guidances related to nonclinical and regulatory issues. Prior to returning to FDA in 2013, he spent five years as a nonclinical/regulatory consultant where he assisted pharmaceutical companies in designing and conducting nonclinical programs including safety pharmacology studies. In a previous tenure at FDA, Tim was a primary nonclinical reviewer and then supervisor in the Divisions of Pulmonary and Allergy Products and Anesthetic, Critical Care and Addiction Products.
James A. Popp DVM, PhD
Dr. Popp is widely recognized for his research and leadership contributions in toxicology and toxicological pathology. He received a Doctor of Veterinary Medicine degree followed by a PhD degree in Comparative Pathology. He has also completed pathology residency training leading to certification as a Diplomate of the American College of Veterinary Patholog. Following postdoctoral training in biochemical pathology and chemical carcinogenesis, he served on the faculty of the University of Florida before joining the Chemical Industry Institute of Toxicology. Over the ensuing 15 years Dr. Popp developed and directed a productive research program in hepatotoxicity and hepatocarcinogenesis with emphasis on liver tumor promotion. During part of his tenure at CIIT, he served as a Department Head and Vice President of the Institute. He has held several Vice President positions overseeing toxicology programs in the pharmaceutical industry for 11 years before founding Stratoxon LLC, a toxicology consulting organization. Dr. Popp has served in the leadership of several professional societies including the positions of President of the Society of Toxicologic Pathology, President of The Academy of Toxicological Sciences and President of The Society of Toxicology. Dr. Popp is a frequent advisor to governmental toxicology efforts including service as Chair of the Board of Scientific Advisors for the US Food and Drug Administration National Center for Toxicological Research.
Mark Powley, PhD
Mark received a PhD in toxicology from Purdue University and completed postdoctoral training at the University of North Carolina. He was subsequently employed in the pharmaceutical industry where his responsibilities included serving as study director, providing toxicokinetic support, and contributing to in silico evaluations for predicting mutagenicity. In 2009, Mark moved to US FDA Center for Drug Evaluation and Research (CDER) where he currently works as a pharmacology/toxicology reviewer in the Office of New Drugs (OND). In addition to reviewing nonclinical data, Mark is involved with the Computational Toxicology Consultation Service and co-chairs the CDER Pharmacology/Toxicology Genetic Toxicology and Computational Toxicology Subcommittees. He is also a past Chair of the Genetic Toxicology Association Board of Directors.
Thomas J. Steinbach, DVM
Dr. Steinbach received his DVM from the College of Veterinary Medicine at the University of Minnesota in 1999. In 2002 he entered residency training for veterinary pathology at the Armed Forces Institute of Pathology and received board certification in 2005. He served as the Chief of Pathology for the Naval Medical Research Center from 2005 to 2008 and then as the Director, Division of Pathology at the Walter Reed Army Institute of Research until 2012. In 2006, Dr. Steinbach joined Experimental Pathology Laboratories as a part-time consultant pathologist. In 2012 he joined EPL full time as a senior pathologist and in 2014 became director of the North Carolina laboratory. His areas of interest include electron microscopy, juvenile toxicology, and nanoparticle pathology.